Gadaleta C, Catino A, Ranieri G, Armenise F, Colucci G, Lorusso V, Cramarossa A, Fiorentini G, Mattioli V
Unità Operativa di Radiologia Interventistica, IRCCS Oncologico Bari, Italy.
J Chemother. 2004 Nov;16 Suppl 5:86-9. doi: 10.1080/1120009x.2004.11782394.
Radiofrequency thermal ablation (RFA) is a new, minimally invasive technique offered in the treatment of various neoplasms. RFA produces ionic agitation within the area to be treated, resulting in the heating of neoplastic tissue using a radiofrequency generator. Well defined areas of coagulative necrosis are formed, thereby destroying the tumor. Percutaneous CT-guided RFA was performed in 34 patients with 69 lung neoplasms. Six patients were affected by primary Non-Small Cell Lung Cancer (NSCLC), and 28 patients presented with metastatic lung nodules originating in various solid tumors. Patients were considered ineligible for surgery for the following reasons: medical comorbidities; technical reasons; severe respiratory insufficiency; refusal of surgery. Adequacy of treatment was assessed by CT-Scan and Nuclear Magnetic Resonance (NMR) with gadolinium. A median follow-up of 9 months (3-25 months) resulted in 30 patients evaluable for response with a total of 63 nodules to be treated, 58 of which achieved complete necrotic response. Relapse occurred in 5/63 treated nodules. In 2 of these patients, relapse occurred exclusively in the treated nodules, whereas in the other 3 patients, relapse occurred in the treated nodules as well as at distant sites. 9 patients are alive and disease free. Pneumothorax requiring pleural drainage was the main complication, observed in 16% of the treatment sessions. Lung RFA has shown itself to be a safe and feasible option in the treatment of lung neoplasms in patients otherwise ineligible for surgery. The high rate of complete responses obtained in our study (92%) suggests that further investigation of lung RFA, combined with chemotherapy and/or radiation therapy is warranted with the objective of improving local disease control and survival rates.
射频热消融(RFA)是一种用于治疗各种肿瘤的新型微创技术。RFA在待治疗区域产生离子搅动,通过射频发生器加热肿瘤组织,形成界限清晰的凝固性坏死区域,从而破坏肿瘤。对34例患有69个肺肿瘤的患者进行了经皮CT引导下的RFA。6例患者患有原发性非小细胞肺癌(NSCLC),28例患者表现为源自各种实体瘤的肺转移结节。患者因以下原因被认为不适合手术:合并内科疾病;技术原因;严重呼吸功能不全;拒绝手术。通过CT扫描和钆增强核磁共振(NMR)评估治疗的充分性。中位随访9个月(3 - 25个月),30例患者可评估反应,共63个结节待治疗,其中58个结节达到完全坏死反应。63个治疗结节中有5个复发。在这些患者中,2例仅在治疗结节复发,而其他3例患者在治疗结节以及远处部位均有复发。9例患者存活且无疾病。需要胸腔引流的气胸是主要并发症,在16%的治疗过程中观察到。对于不适合手术的患者,肺RFA已证明是治疗肺肿瘤的一种安全可行的选择。我们研究中获得的高完全缓解率(92%)表明,为了提高局部疾病控制率和生存率,有必要进一步研究肺RFA联合化疗和/或放疗。